Skip to main content

Table 3 Adherence (MPR) in different Interferon Beta formulations

From: Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy)

 

Avonex®

Betaferon®

Extavia®

Plegridy®

Rebif®

MPR

89.1 ± 2.5%

84.5 ± 2.9%

88.1 ± 2.6%

100. ± 3.4%

86.9 ± 3.0%

Coeff

0.83

−3.53

−1.07

7.43

reference

95%CI

−1.87, 3.53

−6.84, −0.23

−8.40, 6.24

2.79, 12.07

 

p-value

0.54

0.03

0.77

< 0.01

 
  1. Table shows adherence measured as MPR, in different Interferon Beta formulations. Coeff, 95%CI, and p-values are reported from mixed effect linear regression models adjusted by age, sex, and treatment duration (Rebif® was used as reference in the statistical models)
Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us